Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.

Enliven Therapeutics Inc.

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Enliven Therapeutics, with a price target of $45.00. According ...

JonesTrading Keeps Their Buy Rating on Enliven Therapeutics (ELVN)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Enliven Therapeutics today and set a price target of $53.00. According to TipRanks, ...

LifeSci Capital Keeps Their Buy Rating on Enliven Therapeutics (ELVN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioAge Labs, Inc. (BIOA) and Enliven Therapeutics (ELVN). BioAge ...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ELVN	$42.65	-1.18%	928.61K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ELVN	$42.65	-1.2%	928.61K
3
4
5
6

ELVN

ELVN

Dividend Overview

Get Enliven Therapeutics Inc. Data in Excel

Get Enliven Therapeutics Inc. Data in Excel